GDTC (CytoMed Therapeutics) Beginning Cash Position: $2.21 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GDTC CytoMed Therapeutics Ltd GDTC
27 GF Score
Price $0.99
! 2 Warning Signs
View Full Analysis

What is CytoMed Therapeutics Beginning Cash Position?

CytoMed Therapeutics GDTC +12.50% 27 Beginning Cash Position is $2.21 Mil as of Dec. 2025. GuruFocus rates GDTC with a GF Score™ of 27/100. The stock has 2 warning signs investors should review.

CytoMed Therapeutics's Beginning Cash Position for the quarter that ended in Dec. 2025 was $2.21 Mil.

CytoMed Therapeutics's quarterly Beginning Cash Position increased from Dec. 2024 ($2.39 Mil) to Jun. 2025 ($3.66 Mil) but then declined from Jun. 2025 ($3.66 Mil) to Dec. 2025 ($2.21 Mil).

CytoMed Therapeutics's annual Beginning Cash Position increased from Dec. 2023 ($1.19 Mil) to Dec. 2024 ($4.61 Mil) but then declined from Dec. 2024 ($4.61 Mil) to Dec. 2025 ($3.64 Mil).

CytoMed Therapeutics Beginning Cash Position Related Terms

CytoMed Therapeutics Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for CytoMed Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytoMed Therapeutics Beginning Cash Position Chart

CytoMed Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial 0.65 1.86 1.19 4.61 3.64

CytoMed Therapeutics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 3.75 6.66 2.39 3.66 2.21
GDTC
27GF Score
CytoMed Therapeutics Ltd GDTC
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CytoMed Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $2.21 Mil mean?
CytoMed Therapeutics (GDTC) has a Beginning Cash Position of $2.21 Mil as of Dec. 2025. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on CytoMed Therapeutics and its competitors.
Is CytoMed Therapeutics' Beginning Cash Position too high?
CytoMed Therapeutics' current Beginning Cash Position is $2.21 Mil. Overall, CytoMed Therapeutics has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does CytoMed Therapeutics' Beginning Cash Position compare to LEXX and INAB?
CytoMed Therapeutics' Beginning Cash Position of $2.21 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on CytoMed Therapeutics and its competitors. CytoMed Therapeutics's current Beginning Cash Position is $2.21 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoMed Therapeutics stock overvalued right now?
CytoMed Therapeutics (GDTC) has a current Beginning Cash Position of $2.21 Mil. The current Beginning Cash Position is $2.21 Mil. CytoMed Therapeutics' overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For CytoMed Therapeutics (GDTC), the current Beginning Cash Position is $2.21 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CytoMed Therapeutics Business Description

Other Exchanges F98:Germany
Address 1 Commonwealth Lane, No. 08-22 One Commonwealth, Singapore, SGP, 149544
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
27GF Score

Get the complete analysis for GDTC

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.99
Price